Protara Therapeutics financials
$3.21−1.23%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating income | -$64.5M | -$49.2M | -$43.6M | -$67.1M | -$47.5M | -$34.4M |
| Net income | -$57.4M | -$44.6M | -$40.4M | -$66.0M | -$47.3M | -$34.0M |
| Net margin | — | — | — | — | — | — |
| Diluted EPS | $-1.34 | $-2.17 | $-3.57 | $-5.86 | $-4.21 | $-4.70 |
| EBITDA | -$64.2M | -$48.8M | -$43.3M | -$35.9M | -$45.6M | -$34.3M |
| Operating cash flow | -$56.4M | -$35.8M | -$37.6M | -$26.5M | -$34.5M | -$23.4M |
| Free cash flow | -$56.5M | -$35.9M | -$37.6M | -$26.6M | -$35.1M | -$24.3M |
| Diluted shares | 42.8M | 20.6M | 11.3M | 11.3M | 11.2M | 7.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $49.7M | $162.8M | $39.6M | $24.1M | $35.7M | $168.6M |
| Short-term investments | $105.9M | $7.5M | $26.0M | $60.2M | $55.5M | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $209.5M | $181.5M | $79.0M | $113.3M | $172.6M | $203.2M |
| Total liabilities | $13.1M | $14.3M | $10.6M | $11.2M | $10.7M | $3.9M |
| Shareholders' equity | $196.4M | $167.1M | $68.3M | $102.1M | $161.9M | $199.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology